SARS-CoV2: From speculation to mechanism in pulmonary arterial hypertension
19 February 2025
A PVRI 2024 Digital webinar
19 February 2025, 3pm GMT
Presentations
- SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE2
- Antifibrotic therapies for pulmonary fibrosis-induced pulmonary hypertension caused by SARS-CoV-2
- Perfusion imaging of the pulmonary vasculature after SARS-CoV-2 infection
- Endothelial biomarkers of disease severity in SARS-CoV-2 infected patients Grazyna Kwapiszewska, Medical University of Graz
Moderated by Gustavo Heresi, Cleveland Clinic, Ghazwan Butrous, University of Kent, and Jean Elwing, University of Cincinnati
Speakers & moderators
Gustavo Heresi , Cleveland Clinic, USA
Ghazwan Butrous, University of Kent, UK
Jean Elwing, University of Cincinnati, USA
Grazyna Kwapiszewska, Medical University of Graz, Austria
Additional comments are available to members. Login or register to become a member today
RegisterorLogin to view